Pluristem Therapeutics Inc. (PSTI)

0.62
0.04 7.10
NASDAQ : Health Technology
Prev Close 0.57
Open 0.58
Day Low/High 0.57 / 0.63
52 Wk Low/High 0.50 / 1.38
Volume 975.33K
Avg Volume 375.30K
Exchange NASDAQ
Shares Outstanding 149.74M
Market Cap 80.24M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Pluristem And U.S. Department Of Defense To Announce Data From Studies Testing PLX-R18 As A Prophylactic Treatment For Acute Radiation Syndrome At RITN

Pluristem And U.S. Department Of Defense To Announce Data From Studies Testing PLX-R18 As A Prophylactic Treatment For Acute Radiation Syndrome At RITN

Data will be jointly presented at the upcoming 2019 Radiation Injury Treatment Network (RITN) Workshop on July 31st HAIFA, Israel, July 17, 2019 (GLOBE NEWSWIRE) --   Pluristem Therapeutics Inc.

Pluristem Therapeutics' CEO Issues Shareholder Letter

Pluristem Therapeutics' CEO Issues Shareholder Letter

HAIFA, Israel, July 02, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its...

First Week Of PSTI December 20th Options Trading

First Week Of PSTI December 20th Options Trading

Investors in Pluristem Therapeutics Inc saw new options become available this week, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Roger Jeffs, Former Co-CEO Of United Therapeutics, Joins Pluristem's Strategic Advisory Board

Roger Jeffs, Former Co-CEO Of United Therapeutics, Joins Pluristem's Strategic Advisory Board

Jeffs led United Therapeutics from its founding until 2016 and led Amgen's Neupogen clinical programs

Pluristem's PLX-R18 Improves Hematopoietic Transplantation As Reported In Scientific Journal Frontiers In Medicine

Pluristem's PLX-R18 Improves Hematopoietic Transplantation As Reported In Scientific Journal Frontiers In Medicine

Findings support Pluristem's ongoing Phase I study of PLX-R18 in hematopoietic recovery following hematopoietic cell transplantation

Peer-Reviewed Article Published On Pluristem's PLX-PAD Cells' Mechanism Of Action To Restore Blood Flow In Ischemic Tissue

Peer-Reviewed Article Published On Pluristem's PLX-PAD Cells' Mechanism Of Action To Restore Blood Flow In Ischemic Tissue

Data supports advanced PLX-PAD clinical studies including dosing regimen, systemic therapeutic effects and superiority of the cells over cytokines

Pluristem Expands Its Reach In The Treatment Of Impaired Hematopoietic Systems With A European Patent Covering PLX-R18 In Chemotherapy, ARS, Genetic Disorders And Autoimmune Diseases

Pluristem Expands Its Reach In The Treatment Of Impaired Hematopoietic Systems With A European Patent Covering PLX-R18 In Chemotherapy, ARS, Genetic Disorders And Autoimmune Diseases

Patent significantly expands potential indications for PLX-R18 and grants Pluristem broad coverage in the treatment of damaged hematopoietic systems

FDA Grants Pluristem Orphan Drug Designation For Its PLX-R18 Cell Therapy As Treatment For Acute Radiation Syndrome

FDA Grants Pluristem Orphan Drug Designation For Its PLX-R18 Cell Therapy As Treatment For Acute Radiation Syndrome

Pluristem's ARS program is developed and funded by the U.S. National Institutes of Health and the U.S. Department of Defense, and is in preparation for a pivotal study

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis

Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.

TheStreet Quant Rating: D- (Sell)